Bioorganic & Medicinal Chemistry 17 (2009) 427

Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry

journal homepage: www.elsevier.com/locate/bmc

Corrigendum

Corrigendum to "Fluorinated methylenecyclopropane analogues of nucleosides. Synthesis and antiviral activity of (*Z*)- and (*E*)-9-{[(2-fluoromethyl-2-hydroxymethyl)-cyclopropylidene]methyl}adenine and -guanine" [Bioorg. Med. Chem. 16 (2008) 2148–2155]

Chengwei Li [a], Mark N. Prichard [b], Brent E. Korba [c], John C. Drach [d], Jiri Zemlicka [a,*]

[a] *Developmental Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, 110 E. Warren Ave., Detroit, MI 48201-1379, USA*
[b] *Department of Pediatrics, The University of Alabama School of Medicine, Birmingham, AL 35233, USA*
[c] *Division of Molecular Biology and Immunology, Georgetown University Medical Center, Rockville, MD 20850, USA*
[d] *Department of Biologic and Materials Sciences, School of Dentistry, University of Michigan, Ann Arbor, MI 48019-1078, USA*

The following items should be corrected:

Page 2151, Table 3: Results for drugs **15a**, **15b**, **16a**, and **16b** could not be repeated and an amended Table 3 is given below.

Page 2148, Abstract line 5: the sentence "The adenine *Z*-isomer **15a** was found to be a potent inhibitor of Epstein–Barr virus (EBV) in vitro with EC_{50}/CC_{50} (μM) 0.5/55.7." should be deleted.

Table 3
Inhibition of replication of EBV with fluoromethyl methylenecyclopropane nucleoside analogs[a]

Compound	EC_{50}/CC_{50} (μM)[b]	Selectivity index
2b	0.22/>45[c]	>205
5a	6.8/>213	>31.3
5b	8.0/>199	>24.9
6a	167/>209[d]	>1.25
6b	29.1/>199[e]	>6.8
15a	>20/24	<1.2
15b	>20/26	<1.3
16a	>20/96	<4.8
16b	69/82	1.2

[a] Akata cells, DNA hybridization assay. Acyclovir as a control had EC_{50} 3.1 μM.
[b] Results for analogues **5a**–**6b** were taken from Ref. 7 (DNA hybridization assay in Daudi cells).
[c] Data from Ref. 22.
[d] EC_{50} 2.3 μM in viral capsid immunofluorescence (VCA) ELISA and 3.6 μM in Daudi cells (DNA hybridization).
[e] EC_{50} < 0.32 μM in VCA ELISA.

Page 2148, Abstract line 6: the sentence "Compounds **15b**, **16a**, and **16b** were also active but at higher concentrations, EC_{50}/CC_{50} (μM) 3.2–7.5/53.6–64.1." should read "Compounds **15a**, **15b**, **16a**, and **16b** were not active against Epstein–Barr virus (EBV)."

Page 2150–51, Section 2.3, lines 7–23: the text reading "They were all effective against EBV in Akata cells using a DNA hybridization assay.[22] The adenine analogue **15a** was the most potent (Table 3) and least cytotoxic. It was more effective than cyclopropavir (**2b**). The *E*-isomer **16a** and guanine derivatives **15b** and **16b** were less effective than **15a**. Interestingly, a somewhat similar anti-EBV activity pattern was found with *Z*- and *E*-isomers of fluoroanalogues[7] **5a**, **5b**, **6a**, and **6b** which can be regarded as lower homologues of **15a**, **15b**, **16a**, and **16b**. However, an exact comparison is not possible because of the differences in assays. In the series of fluoroanalogues **7**–**12** only adenine *Z*-isomer[8] **9a** was effective against EBV. It is likely that the mechanism of anti-EBV action of analogues **15a**, **15b**, **16a**, and **16b** includes their phosphorylation to triphosphates which then inhibit the viral DNA polymerase as suggested for other fluorinated methylenecyclopropane analogues.[7,8]" should read "None of these analogues exhibited antiviral activity against EBV that could be separated from their cytotoxicity."

Page 2151, Section 3, line 3: the sentence "All analogues were inhibitors of replication of EBV in Akata cells with adenine derivative **15a** being the most potent with EC_{50}/CC_{50} (μM) 0.5/55.7." should be deleted.

DOI of original article: 10.1016/j.bmc.2007.11.082
* Corresponding author. Tel.: +1 313 578 4288; fax: +1 313 832 7294.
E-mail address: zemlicka@karmanos.org (J. Zemlicka).

0968-0896/$ - see front matter
doi:10.1016/j.bmc.2007.11.085